EMH Schweizerischer Ärzteverlag AG
Farnsburgerstrasse 8
CH-4132 Muttenz
+41 (0)61 467 85 44
support@swisshealthweb.ch
www.swisshealthweb.ch
Published on 09.09.2020
Atrial fibrillation (AF) is common in the ACS setting and associated with increased risk of in-hospital mortality. Although AF did not represent an independent prognosticator in ACS, a progressive increase on in-hospital death was observed when combining type of ACS and presence/absence of AF.
ACS-AF cohort | |
---|---|
Number | 187 |
Age (years) | 74 ± 11 |
Female (%) | 31 |
ACS STEMI (%) | 43.8 |
ACS NSTEMI (%) | 56.2 |
Cardiogenic shock (%) | 10.7 |
New onset AF (%) | 46 |
CHADS2-VASC score | 4.1 ± 1.5 |
HAS-BLED score | 3 ± 1.2 |
LVEF (%) | 46 ± 12.5 |
Radial access (%) | 19.5 |
Acute treatment | |
– PCI (%) | 64.5 |
– CABG (%) | 7.5 |
– Medical (%) | 28 |
Mortality | OR | 95% CI | p-value |
---|---|---|---|
AF− AF+ | 1.00 (base) 1.44 | – (0.78–2.65) | – 0.246 |
ST− ST+ | 1.00 (base) 5.56 | – (3.38–9.15) | – 0.0001 |
Sex female Sex male | 1.00 (base) 1.03 | – (0.65–1.64) | – 0.887 |
Age, per year | 1.06 | (1.04–1.08) | 0.0001 |
Triple therapy | SAPT + OAC | DAPT | p-value | |
---|---|---|---|---|
Number | 45 | 23 | 88 | - |
Age (years) | 77 ± 7 | 76 ± 11 | 71 ± 12 | 0.04 |
Gender female (%) | 31.3 | 21.7 | 32.7 | 0.65 |
STEMI/NSTEMI (%) | 33.3/66.7 | 39.1/60.9 | 50/50 | 0.14 |
Cardiogenic shock (%) | 6.3 | 13 | 13.3 | 0.42 |
New onset AF (%) | 41.7 | 60.9 | 42.9 | 0.27 |
CHADS2-VASC score | 4± 1.5 | 4.7± 1.9 | 4.1± 1.6 | 0.24 |
HAS-BLED score | 3 ± 1.3 | 3.1 ± 1 | 2.9 ± 1.3 | 0.64 |
LVEF (%) | 47 ± 12.3 | 43 ± 9.8 | 46 ± 13.1 | 0.35 |
Radial access (%) | 20.8 | 8.7 | 21.4 | 0.41 |
Acute treatment | ||||
– PCI, n (%) | 34 (75.6) | 11 (47.8) | 62 (70.5) | 0.04 |
– CABG, n (%) | 0 (0) | 6 (26.1) | 2 (2.2) | 0.001 |
– Medical, n (%) | 11 (24.4) | 6 (26.1) | 24 (27.3) | 0.94 |
1-year outcomes | Triple therapy n = 45 | AOC + SAPT n = 23 | DAPT n = 88 | p-value* |
---|---|---|---|---|
Death n; HR; 95% CI | n = 3 HR = 1.48 95% CI 0.33–6.63 | n = 3 HR = 3.06 95% CI [0.68 -13.67] | n = 4 HR = 1 (base) | 0.31 |
MACE n; HR; 95% CI | n = 7 HR = 1.95 95% CI 0.68–5.51 | n = 3 HR = 1.83 95% CI [0.47 -7.10] | n = 7 HR = 1 (base) | 0.41 |
Major bleeding n; HR; 95% CI | n = 5 HR = 1.68 95% CI 0.51–5.50 | n = 0 – – | n = 6 HR = 1 (base) | 0.27 |
1 year outcomes | Triple therapy n = 45 | OAC + SAPT n = 23 | DAPT n = 88 | p-value* |
---|---|---|---|---|
Deaths HR; 95% CI | HR = 2.68 95% CI 0.39–18.51 | HR = 3.66 95% CI 0.44–30.26 | HR = 1 (base) | 0.44 |
MACE HR; 95% CI | HR = 3.41 95% CI 0.93–12.45 | HR = 1.52 95% CI 0.25–9.20 | HR = 1 (base) | 0.17 |
Major bleeding HR; 95% CI | HR = 2.33 95% CI 0.64–8.52 | – – | HR = 1 (base) | 0.13 |
Published under the copyright license.
"Attribution - Non-Commercial - NoDerivatives 4.0"
No commercial reuse without permission.
See: emh.ch/en/emh/rights-and-licences/